Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies

Dermatol Ther. 2021 Jan;34(1):e14438. doi: 10.1111/dth.14438. Epub 2020 Dec 6.

Abstract

Oral isotretinoin is the most effective treatment for moderate to severe acne and its side effects are mostly dose-dependent. Low dose isotretinoin (0.5 mg/kg/day for 1 week every 4 weeks for 6-months) could be effective and even in its end result, comparable with high or optimal doses. In this systematic review, we aimed to sum up the results of clinical trials regarding indications, dosage, prescription protocol, effectiveness, side effects, patient satisfaction, recurrence rate, and follow-up period of low dose isotretinoin in treatment of acne. Cochrane, Google Scholar, Science Direct, PubMed, and Medline were searched. A total of 460 articles were searched electronically and 382 articles were excluded. About 4 were non-English and 2, before 1980. The full text of 72 articles was reviewed. Finally 15 documents met the inclusion criteria for entering this systematic review. The standard dose of isotretinoin is 0.5-1 mg/kg/day for 4 months with a total dose of 120-140 mg/kg/day. Daily doses between 0.1 and 0.3 mg/kg can be recommended for more than 6 months due to the occurrence of fewer side effects and more economical concerns. For greater effectiveness, it could be combined with other medications.

Keywords: acne; alternate day dose; dosage; effectiveness; follow up; isotretinoin; low dose; recurrence; retinoic acid; retinoid; safety; satisfaction; side effect; systematic review; systemic retinoid; treatment; under-optimal dose.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Acne Vulgaris* / diagnosis
  • Acne Vulgaris* / drug therapy
  • Dermatologic Agents* / adverse effects
  • Follow-Up Studies
  • Humans
  • Isotretinoin / adverse effects
  • Personal Satisfaction

Substances

  • Dermatologic Agents
  • Isotretinoin